

Title (en)  
COMBINATION OF MTP INHIBITORS OR APOB SECRETION INHIBITORS WITH FIBRATES FOR USE AS DRUGS

Title (de)  
KOMBINATION VON MTP INHIBITOREN ODER apoB-SEKRETIONS-INHIBITOREN MIT FIBRATEN ZUR VERWENDUNG ALS ARZNEIMITTEL

Title (fr)  
COMBINAISON D'INHIBITEURS DE MTP OU D'INHIBITEURS DE SECRETIONS APOB AVEC DES FIBRATES EN VUE D'UNE UTILISATION COMME MEDICAMENT

Publication  
**EP 1465613 A2 20041013 (DE)**

Application  
**EP 03702391 A 20030107**

Priority  
• DE 10200633 A 20020110  
• DE 10256184 A 20021202  
• EP 0300057 W 20030107

Abstract (en)  
[origin: WO03057205A2] The invention relates to the use of fibrates for reducing the hepatic toxicity of MTP inhibitors and to pharmaceutical compositions that contain an MTP inhibitor and a fibrate.

IPC 1-7  
**A61K 31/167**

IPC 8 full level  
**A61K 31/5377** (2006.01); **A61K 31/167** (2006.01); **A61K 31/17** (2006.01); **A61K 31/192** (2006.01); **A61K 31/195** (2006.01); **A61K 31/216** (2006.01); **A61K 31/381** (2006.01); **A61K 31/40** (2006.01); **A61K 31/4025** (2006.01); **A61K 31/4035** (2006.01); **A61K 31/4155** (2006.01); **A61K 31/4164** (2006.01); **A61K 31/4184** (2006.01); **A61K 31/4196** (2006.01); **A61K 31/4245** (2006.01); **A61K 31/425** (2006.01); **A61K 31/433** (2006.01); **A61K 31/437** (2006.01); **A61K 31/438** (2006.01); **A61K 31/4439** (2006.01); **A61K 31/445** (2006.01); **A61K 31/4468** (2006.01); **A61K 31/454** (2006.01); **A61K 31/455** (2006.01); **A61K 31/47** (2006.01); **A61K 31/4709** (2006.01); **A61K 31/4725** (2006.01); **A61K 31/496** (2006.01); **A61K 31/501** (2006.01); **A61K 31/506** (2006.01); **A61K 31/519** (2006.01); **A61K 45/06** (2006.01); **A61P 1/16** (2006.01); **A61P 1/18** (2006.01); **A61P 3/04** (2006.01); **A61P 3/06** (2006.01); **A61P 3/10** (2006.01); **A61P 9/10** (2006.01)

CPC (source: EP)  
**A61K 31/167** (2013.01); **A61K 31/17** (2013.01); **A61K 31/192** (2013.01); **A61K 31/195** (2013.01); **A61K 31/216** (2013.01); **A61K 31/40** (2013.01); **A61K 31/4025** (2013.01); **A61K 31/4164** (2013.01); **A61K 31/4184** (2013.01); **A61K 31/437** (2013.01); **A61K 31/438** (2013.01); **A61K 31/4439** (2013.01); **A61K 31/4468** (2013.01); **A61K 31/454** (2013.01); **A61K 31/47** (2013.01); **A61K 31/4725** (2013.01); **A61K 31/496** (2013.01); **A61K 31/501** (2013.01); **A61K 31/519** (2013.01); **A61K 45/06** (2013.01); **A61P 1/16** (2017.12); **A61P 1/18** (2017.12); **A61P 3/04** (2017.12); **A61P 3/06** (2017.12); **A61P 3/10** (2017.12); **A61P 9/10** (2017.12)

Citation (search report)  
See references of WO 03057205A2

Citation (examination)  
DE 10132686 A1 20030116 - BOEHRINGER INGELHEIM PHARMA [DE]

Designated contracting state (EPC)  
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT SE SI SK TR

DOCDB simple family (publication)  
**WO 03057205 A2 20030717**; **WO 03057205 A3 20040401**; AR 038178 A1 20050105; AU 2003205570 A1 20030724; AU 2003205570 A8 20030724; CA 2471566 A1 20030717; EP 1465613 A2 20041013; JP 2005525309 A 20050825; PE 20030924 A1 20031217; TW 200402292 A 20040216; UY 27610 A1 20030829

DOCDB simple family (application)  
**EP 0300057 W 20030107**; AR P030100056 A 20030110; AU 2003205570 A 20030107; CA 2471566 A 20030107; EP 03702391 A 20030107; JP 2003557563 A 20030107; PE 2003000036 A 20030109; TW 92100321 A 20030108; UY 27610 A 20030107